A patient walks into urgent care with a cough and an earache. The visit takes fifteen minutes. The provider diagnoses otitis media and a nonspecific cough, prescribes a fluoroquinolone antibiotic and a short course of steroids, and the patient goes home. Routine. Unremarkable. The kind of visit that happens thousands of times a day in clinics across the country.
Except the patient is a 67-year-old woman, which places her in the highest-risk demographic for fluoroquinolone-associated tendon injury. The FDA has carried a boxed warning on fluoroquinolones since 2008 specifically flagging the risk of tendinitis and tendon rupture, a risk that increases significantly in patients over 60 and in patients taking concurrent corticosteroids. Weeks after completing the prescription, she develops Achilles tendinopathy so severe she cannot walk. Months of rehabilitation follow. Then a lawsuit.
This is not a rare or unusual chain of events. It’s a prescribing decision that looked routine in the moment and became a malpractice claim because of what the prescriber didn’t account for: FDA warnings, patient risk factors, drug interactions, and whether the clinical documentation supported the prescription in the first place.
For PAs and NPs with prescriptive authority, particularly those practicing in urgent care, primary care, and full practice authority states where prescribing decisions rest entirely with you, this is the category of risk worth understanding deeply.
Why Do Prescribing Claims Happen to Good Clinicians?
The majority of prescribing-related malpractice claims don’t involve reckless or incompetent providers. They involve experienced clinicians who made a decision that seemed clinically reasonable at the time but failed to account for one or more factors that, in retrospect, changed the risk calculus.
The most common patterns in prescribing claims include:
Prescribing a medication without a clear clinical indication. This is the foundational issue in many claims. If the medical record doesn’t document findings that support the diagnosis, and the diagnosis doesn’t justify the medication prescribed, the prescriber is exposed. In the scenario above, the expert review found that the documented exam findings (normal vitals, clear lungs, no evidence of bacterial infection) did not support the use of a fluoroquinolone antibiotic. If there’s no justifiable indication in the chart, the prescription becomes indefensible.
Failing to account for patient risk factors. Age, kidney function, concurrent medications, pregnancy status, allergy history. These factors are in the chart (or should be), and they change whether a given drug is appropriate. Fluoroquinolone tendon risk, for example, is specifically elevated in patients over 60, patients on corticosteroids, and transplant recipients. Prescribing a fluoroquinolone with concurrent steroids to a 67-year-old patient checks multiple risk boxes simultaneously.
Prescribing drug combinations with known interaction risks. Some interactions are well documented and carry FDA-level warnings. Fluoroquinolones combined with corticosteroids is one. Research published in Frontiers in Pharmacology found that 85% of tendon rupture cases associated with fluoroquinolones developed symptoms within one month when oral corticosteroids were used concurrently. The risk of tendon rupture jumped from 3.73 per 10,000 patient-years with fluoroquinolones alone to 21.2 per 10,000 patient-years when steroids were added. That’s a nearly sixfold increase.
Documentation that doesn’t support the clinical decision. Even when the prescribing decision itself was sound, a chart that doesn’t reflect the clinical reasoning leaves the provider without a defense. If the documentation says “cough” and “otitis media” but contains no exam findings for the ear, no rationale for the antibiotic choice, and no note about the patient’s age-related risk factors, the defense attorney has nothing to work with.
What the FDA Boxed Warning on Fluoroquinolones Actually Says
Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, and others) are among the most commonly prescribed antibiotics in the United States. They’re effective against a broad range of bacterial infections. They’re also the subject of one of the most extensive series of FDA safety warnings in pharmaceutical history.
The timeline matters because it establishes what prescribers are expected to know:
2008: The FDA added a boxed warning, the most serious type of drug warning, flagging the increased risk of tendinitis and tendon rupture. The Achilles tendon is the most commonly affected. Risk factors include age over 60, concurrent corticosteroid use, and organ transplant recipients.
2013: The FDA updated labels to warn about the risk of irreversible peripheral neuropathy.
2016: The FDA issued a comprehensive safety communication advising that fluoroquinolones should be reserved for conditions where no other treatment option is available, specifically calling out acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections as conditions where other antibiotics should be tried first. The FDA noted that the risks of fluoroquinolones “generally outweigh the benefits” for patients with these conditions.
2018: The FDA added warnings about the risk of aortic rupture.
What this means for prescribers: the FDA’s position is that fluoroquinolones should not be used as first-line agents for conditions where safer alternatives exist. Prescribing a fluoroquinolone for a condition that doesn’t have a clear bacterial etiology, to a patient with multiple risk factors, without documenting the clinical rationale, is a deviation from both FDA guidance and the accepted standard of care. And it’s exactly the kind of deviation that expert witnesses identify when reviewing malpractice claims.
How Documentation Turns a Bad Outcome Into a Defensible Case (or Doesn’t)
The difference between a defensible prescribing decision and an indefensible one usually isn’t the decision itself. It’s the documentation.
When a malpractice claim is reviewed, the medical record is the primary evidence. If the chart shows a thorough exam, a documented differential diagnosis, a rationale for the medication choice, a consideration of risk factors, and a discussion of alternatives with the patient, the prescriber has a defense even if the outcome was bad.
If the chart shows a one-line diagnosis and a prescription with no supporting findings, no rationale, and no evidence that the prescriber considered the patient’s age, drug interactions, or FDA warnings, the defense collapses. The expert witness doesn’t need to prove the prescriber was negligent. They need to show that the documentation doesn’t support the standard of care. An incomplete chart does that work for them.
For PAs and NPs in high-volume settings like urgent care, the documentation pressure is real. You’re seeing patients quickly. The system is designed for throughput. But the chart is what remains after the patient leaves, and it’s what your defense will be built on if a claim arises months or years later.
A few documentation habits that protect prescribers:
- Document the exam findings that support the diagnosis, not just the diagnosis itself
- Note why you chose the specific medication over alternatives
- Record that you considered and addressed relevant risk factors (age, comorbidities, concurrent medications)
- If the patient has risk factors for known drug adverse effects, document that you weighed the risks and benefits
- For high-risk drug categories (fluoroquinolones, opioids, anticoagulants), note that the patient was counseled on potential side effects
Prescribing Liability Is Growing as NP and PA Autonomy Expands
Prescriptive authority has been one of the defining expansions of the NP and PA professions over the past decade. In full practice authority states, NPs prescribe independently. PAs in states with expanded practice categories are gaining prescriptive independence without physician co-signature requirements. Oklahoma NPs gained independent prescriptive authority in November 2025 after a veto override.
This is progress. It means patients have better access to care. But it also means that the prescribing liability that was previously shared with (or absorbed by) a supervising physician now rests squarely on the prescriber. When a PA or NP prescribes independently, the prescription, the clinical reasoning, the documentation, and the outcome are all attributable to them.
An industry claims analysis found that diagnosis-related allegations (which often involve prescribing decisions tied to the diagnosis) account for 37.1% of all NP claims and carry the highest average severity at $385,947. The prescribing decision is frequently the hinge point in these claims: the diagnosis was wrong, so the prescription was wrong, so the patient was harmed.
This doesn’t mean NPs and PAs should prescribe less aggressively. It means they should prescribe more carefully, with documentation that reflects the clinical thought process, risk factor consideration, and medication choice rationale.
What Your Malpractice Policy Should Cover
If a prescribing decision leads to a claim, your professional liability policy is what stands between you and the financial and professional consequences. A few features matter more than others in prescribing-related claims.
Defense outside limits means your legal defense costs don’t reduce the coverage available for a settlement or judgment. Prescribing claims can involve extensive expert review, pharmacology testimony, and clinical documentation analysis. Defense costs add up quickly. With defense outside limits, your full policy limit remains available for the claim itself.
Consent-to-settle ensures that nobody settles a prescribing claim on your behalf without your approval. A settlement is reported to the NPDB regardless of the amount or circumstances, and it can affect your credentialing, insurance panel participation, and employment for years. If you believe your prescribing decision was clinically justified and you want to defend it, consent-to-settle gives you that right.
Licensing board defense as a separate benefit matters because prescribing-related complaints can trigger a board investigation independently of a civil claim. A patient or family member can file a board complaint alleging inappropriate prescribing without filing a lawsuit. Board investigations into prescribing patterns can result in disciplinary action, mandatory continuing education, prescriptive authority restrictions, or license suspension.
Occurrence-based coverage ensures that if a prescribing claim surfaces months or years after the visit (which is common, given that adverse effects like tendinopathy can develop weeks after completing a course of medication), you’re covered regardless of whether you still hold the same policy.
CM&F policies through MedPro Group include all of these features, backed by an A++ (Superior) A.M. Best rating, a 90% trial win rate, and 80% of claims closed without payment.
Key Takeaways
Prescribing-related malpractice claims typically involve clinicians who made a decision that seemed routine but failed to account for patient risk factors, FDA warnings, drug interactions, or documentation requirements.
Fluoroquinolones carry an FDA boxed warning for tendinitis and tendon rupture. The risk increases significantly in patients over 60 and those taking concurrent corticosteroids. The FDA advises reserving fluoroquinolones for conditions where no alternative is available.
Documentation is the difference between a defensible case and an indefensible one. If the chart doesn’t support the diagnosis, the medication choice, and the clinical reasoning, the defense starts from a deficit.
As NP and PA prescriptive authority expands, the liability for each prescribing decision rests more squarely on the individual provider. Diagnosis-related allegations, which often involve prescribing decisions, account for 37.1% of all NP claims at an average severity of $385,947.
When evaluating your coverage, confirm that your policy includes defense outside limits, consent-to-settle, licensing board defense as a separate benefit, and occurrence-based coverage. These are the features that protect you when a routine prescription becomes a claim.
Frequently Asked Questions
- Can a PA or NP be sued for a prescribing decision?Yes. PAs and NPs with prescriptive authority bear direct liability for their prescribing decisions. If a medication causes harm and the prescription was not supported by the clinical documentation, did not account for patient risk factors, or deviated from FDA guidance or the accepted standard of care, the prescriber can be named in a malpractice claim. Both the individual provider and the practice or facility may be named.
- What are the most common prescribing errors that lead to malpractice claims?The most common prescribing-related claims involve prescribing a medication without a clear clinical indication documented in the chart, failing to account for patient risk factors (age, concurrent medications, comorbidities), prescribing drug combinations with known interaction risks, and inadequate documentation of the clinical reasoning behind the prescription. Diagnosis-related allegations, which often involve the prescribing decision tied to the diagnosis, account for 37.1% of all NP claims at an average severity of $385,947.
- Does malpractice insurance cover prescribing liability for NPs and PAs?Yes. Professional liability insurance covers claims arising from prescribing decisions, including claims alleging that a medication was inappropriately prescribed, caused an adverse reaction, or was prescribed without adequate clinical justification. Look for a policy with defense costs paid outside limits, consent-to-settle rights (so no one settles a prescribing claim without your approval), licensing board defense as a separate benefit, and occurrence-based coverage that protects you even if the claim surfaces months or years after the prescription.
